Literature DB >> 26933989

Routine or targeted HIV screening of Indonesian prisoners.

Erni Juwita Nelwan1, Ahmad Isa, Bachti Alisjahbana, Nurlita Triani, Iqbal Djamaris, Ilham Djaja, Herdiman T Pohan, Prisca Zwanikken, Reinout van Crevel, Andre van der Ven, Andre Meheus.   

Abstract

PURPOSE: Routine HIV screening of prisoners is generally recommended, but rarely implemented in low-resource settings. Targeted screening can be used as an alternative. Both strategies may provide an opportunity to start HIV treatment but no formal comparisons have been done of these two strategies. The paper aims to discuss these issues. DESIGN/METHODOLOGY/APPROACH: The authors compared yield and costs of routine and targeted screening in a narcotic prison in Indonesia. Routine HIV screening was done for all incoming prisoners from August 2007-February 2009, after it was switched for budgetary reasons to targeted ("opt-out") HIV screening of inmates classified as people who inject drugs (PWIDs), and "opt-in" HIV testing for all non-PWIDs.
FINDINGS: During routine screening 662 inmates were included. All 115 PWIDs and 93.2 percent of non-PWIDs agreed to be tested, 37.4 percent and 0.4 percent respectively were HIV-positive. During targeted screening (March 2009-October 2010), of 888 inmates who entered prison, 107 reported injecting drug use and were offered HIV testing, of whom 31 (29 percent) chose not to be tested and 25.0 percent of those tested were HIV-positive. Of 781 non-PWIDs, 187 (24 percent) came for testing (opt-in), and 2.1 percent were infected. During targeted screening fewer people admitted drug use (12.0 vs 17.4 percent). Routine screening yielded twice as many HIV-infected subjects (45 vs 23). The estimated cost per detected HIV infection was 338 USD for routine and 263 USD for targeted screening. ORIGINALITY/VALUE: In a resource limited setting like Indonesia, routine HIV screening in prison is feasible and more effective than targeted screening, which may be stigmatizing. HIV infections that remain unrecognized can fuel ongoing transmission in prison and lead to unnecessary disease progression and deaths.

Entities:  

Keywords:  Effectiveness; HIV; Indonesia; Prevention; Prison; Screening

Mesh:

Year:  2016        PMID: 26933989     DOI: 10.1108/IJPH-04-2015-0012

Source DB:  PubMed          Journal:  Int J Prison Health        ISSN: 1744-9200


  6 in total

1.  Adherence to Antiretroviral Therapy Among Incarcerated Persons with HIV: Associations with Methadone and Perceived Safety.

Authors:  Gabriel J Culbert; Agung Waluyo; Melinda Wang; Tissa Aulia Putri; Alexander R Bazazi; Frederick L Altice
Journal:  AIDS Behav       Date:  2019-08

2.  HIV and Viral Hepatitis Among Imprisoned Key Populations.

Authors:  Andrea L Wirtz; Ping T Yeh; Natalie L Flath; Chris Beyrer; Kate Dolan
Journal:  Epidemiol Rev       Date:  2018-06-01       Impact factor: 6.222

3.  Exploring the acceptability of HIV partner notification in prisons: Findings from a survey of incarcerated people living with HIV in Indonesia.

Authors:  Gabriel J Culbert; Agung Waluyo; Valerie A Earnshaw
Journal:  PLoS One       Date:  2020-06-30       Impact factor: 3.240

Review 4.  Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review.

Authors:  Seth Francis-Graham; Nnenna Adaniya Ekeke; Corey Andrew Nelson; Tin Yan Lee; Sulaima El Haj; Tim Rhodes; Cecilia Vindrola; Tim Colbourn; William Rosenberg
Journal:  BMC Health Serv Res       Date:  2019-03-08       Impact factor: 2.655

Review 5.  Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review.

Authors:  J J Ong; K Coulthard; C Quinn; M J Tang; T Huynh; M S Jamil; R Baggaley; C Johnson
Journal:  Curr HIV/AIDS Rep       Date:  2022-02-11       Impact factor: 5.071

6.  The costs of scaling up HIV and syphilis testing in low- and middle-income countries: a systematic review.

Authors:  Rabiah Al Adawiyah; Olga P M Saweri; David C Boettiger; Tanya L Applegate; Ari Probandari; Rebecca Guy; Lorna Guinness; Virginia Wiseman
Journal:  Health Policy Plan       Date:  2021-06-25       Impact factor: 3.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.